Summer Street maintained a Buy rating on Ligand Pharma (NASDAQ: LGND) and raised its price target to $78.00 (from $69.00).
This article: 245 words
-->

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE